induced by influenza A virus (Flu) or phytohaemoagglutinin A (PHA), but had no effect on CD8 + T cell. This is the first report of IDO and TTS regulation by the CTLA-4~B7 system in human CD4 + and CD8 + T cells, and raises the possibility that these two tryptophan modulating enzymes provide an important mechanism for regulating immune responses.
only.
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INTRODUCTION
Indoleamine 2,3-dioxygenase (IDO) and tryptophanyl-tRNA-synthetase (TTS) are cytoplasmic enzymes involved in tryptophan (trp) catabolism and utilization, respectively, and are both induced by interferon-(IFN-) [1] [2] [3] [4] [5] [6] [7] [8] . IDO catalyzes the first step reaction of tryptophan catabolism, the conversion of tryptophan to N-formylkynurenine, and subsequently kynurenine [1] [2] [3] . TTS is the ubiquitous enzyme responsible for the association of tryptophan with its specific tRNA, with the resulting trp-tRNA complex being utilized for protein synthesis [4] [5] [6] [7] [8] . Therefore, IFN-exerts a dual effect on trp metabolism by increasing the rate of degradation of trp in the IDO pathway, and by enhancing the accumulation of this amino acid into trp-tRNA complexes available for protein synthesis.
IDO is strongly expressed in macrophages and dendritic cells (DCs) [9] [10] [11] [12] , and has been shown to be responsible for downmodulating T cell activation and proliferation, through depletion of trp from the microenvironment [9] [10] [11] [12] [13] [14] [15] . Murine studies have also suggested that products of tryptophan catabolism (quinolinic acid and 3-hydroxyanthranilic acid) can induce apoptosis of T cells 16, 17 . In this context, regulation of TTS expression could serve as a mechanism for protecting IDO-expressing cells from trp self-starvation 18 . The trp-tRNA complex would provide a reservoir of the amino acid in a form that is protected from IDO-mediated degradation and directly available for the protein synthesis 18 .
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is transiently expressed on T cells after activation, and can bind both B7.1 (CD80) and B7.2 (CD86) on antigen presenting cells (APCs), with higher affinity than CD28 [19] [20] [21] . CTLA-4 is a negative regulator of T only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013 . bloodjournal.hematologylibrary.org From cell activation, but the mechanisms underlying its inhibitory activity are still not fully understood [20] [21] [22] . Competition with CD28 for binding to B7 molecules and induction of a direct inhibitory signal by CTLA-4 are among the suggested mechanisms [20] [21] [22] .
Recombinant soluble forms of CTLA-4 (CTLA-4-Fc) have been shown to induce IDO expression in murine 23, 24 and, more recently, human DCs 25 . CTLA-4 bound B7 molecules on DCs and triggered IFN-production, resulting in the induction of IDO espression 23, 24 .
Thus, CTLA-4 expressed on activated T cells can stimulate IDO in DCs, providing feedback control of T cell activation itself 24 .
Defects in the immunoregulatory mechanism initiated by IDO have been suggested to be involved in: 1) development of autoimmune conditions, such as multiple sclerosis and autoimmune diabetes 26, 27 ; 2) failure of immune surveillance of tumor cells 28 ; 3) rejection of semiallogenic fetuses [29] [30] [31] [32] [33] [34] ; and 4) the dementia seen in some patients with acquired immunodeficiency syndrome (AIDS) [35] [36] [37] [38] [39] . Recent studies demonstrating the involvement of CTLA-4 in the control of autoimmune conditions [40] [41] [42] [43] [44] and allograft rejection 44, 45 , as well as evidence that CTLA-4 blockade can enhance antitumor responses 46 , also support the functional correlation between CTLA-4 and IDO.
In the present study we used a recombinant soluble form of human CTLA-4 fetal bovine serum (Sigma, St. Louis, MO) in presence of a combination of GM-CSF, IL-4 and TNF-(Immunex, Thousand Oaks, CA). Cultures were initiated with 20ng/ml GM-CSF and 20ng/ml IL-4. On the third day of culture half of the medium was changed and 40ng/ml GM-CSF added. On the sixth day of culture, half of the medium was changed and 90ng/ml GM-CSF and 40ng/ml TNF-were added. Mature DCs (mDCs)
were generated by activation of iDCs by treatment with 50ng/ml soluble CD40L
(Immunex, Thousand Oaks, CA) for 24 hours. In other experiments, cell fractionation was performed before culture with CTLA-4-Fc.
Experiments with recombinant human interferon-(rhIFN-) (Biogen, Cambridge, MA)
were performed using a final concentration of 4µg/ml of rhIFN-. Incubation time varied depending on the analysis performed.
Blocking of B7.1, B7.2 and IFN-with specific monoclonal antibodies (mAb).
Anti-human-B7.1 (CD80) and/or anti-human-B7. under the following conditions: 1) untreated control; 2) CTLA-4-Fc (4µg/ml); 3) rhIFN-(4µg/ml). After 24 hours of culture, supernatants were collected for HPLC, and CD4 + T cells were isolated from PBMCs. CD4 + cells were then isolated from the untreated and the CTLA-4-Fc treated PBMCs, and cultured respectively in absence and presence of CTLA-4-Fc (4µg/ml). After 24 hours of culture supernatants were collected for HPLC.
Detection of tryptophan and kynurenine was performed by HPLC as previosly described 47 . For an inhibitory molecule for IDO, and activated these PBMCs with PHA (1µg/ml) after 48 hours. As shown in Figure 7 and summarized in Table 1 For MHC class II 48-50 , they may acquire some functional characteristics of APCs, including the ability to express IDO when exposed to CTLA-4-Fc. Recent studies using B7 knockout mice showed that the expression of costimulatory molecules on CD4 + T cells is responsible for downmodulating responses to alloantigens, and that this effect is dependent on CTLA-4~B7 interactions between T cells 51 . Our data provide the first report demonstrating that CD4 + T cells can express IDO when exposed to CTLA-4-Fc, suggesting that the immunomodulatory effect of B7 expression on CD4 + T cells may involve tryptophan catabolism.
CD4
Tryptophan is an essential amino acid that is required by all cells to synthesize proteins. The depletion of tryptophan in the microenvironment, which results from IDO overexpression, affects T cell activity without exerting negative effects on the IDOexpressing cells (DCs or macrophages) 12, 15 . It is not known why IDO-expressing cells themselves are not susceptible to tryptophan depletion. One possibility is that activated T lymphocytes have a higher rate of protein synthesis compared to DCs, which could result in a higher sensitivity to IDO-induced tryptophan depletion. It was reported that activated T lymphocytes have increased capacity to synthesize aminoacyl-tRNA with several different amino acids 52, 53 . An alternative, but not mutually exclusive mechanism is that IDO-expressing cells are in some way protected against tryptophan starvation. It has been suggested that IDO-expressing cells avoid the negative effects of tryptophan depletion by increasing the expression of TTS 18 . Tryptophanyl-tRNA-synthetase is the only aminoacyl-tRNA-synthetase whose expression is induced by IFN- 4 8 . This unique property makes TTS a prime candidate for protecting the IDO-expressing cells from tryptophan starvation 18 . Overexpression of TTS in the APCs could permit the production only.
For The mechanism by which IDO inhibits T cell activity is considered to be tryptophan starvation [9] [10] [11] [12] [13] [14] [15] . Because we demonstrated differences in CTLA-4-Fc-induced IDO and TTS expression in CD4 + and CD8 + T cells cultured as unseparated PBMCs, we tested the effect of viral-and mitogen-induced T cell activation on these two T cell subsets. We exposed PBMCs to Flu or PHA, and analyzed the surface expression of the activation markers CD69 and CD38 on CD4 + and CD8 + T cells. In summary, we demonstrate that CTLA-4-Fc molecules interact with B7. For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From
